PDS Biotechnology Corporation (NASDAQ:PDSB) does about 1.95M shares in volume on a normal day but saw 3872471 shares change hands in Friday trading. The company now has a market cap of 62.30M USD and an enterprise value of about $48.73M. Its current market price is $2.95, marking an increase of 1.03% compared to the previous close of $2.92. The 52 week high reached by this stock is $6.16 whilst the lowest price level in 52 weeks is $0.62. The script in recent trading has seen the stock touch a high of $3.26 and a low of $2.82.

PDS Biotechnology Corporation (PDSB) has a 20-day trading average at $3.50 and the current price is -52.11% off the 52-week high compared with 379.44% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.68 and its 200-day simple moving average is $1.93. If we look at the stock’s price movements over the week, volatility stands at 7.67%, which increases to 11.33% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 47.50 to suggest the stock is neutral.

2 analysts observing the PDS Biotechnology Corporation (PDSB) stock have set the 12-month price targets for the company’s shares at between $6.50 and $10.00. The median price target is 64.24% away from the current levels at $8.25.

FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 27, 2020 when Alliance Global Partners initiated the stock to “Buy” and issued a price target of $4. Chardan Capital Markets initiated its price target at $10.

The current price level is -16.41%, 11.36%, and 52.72% away from its SMA20, SMA50, and SMA200 respectively, with the PDSB price moving below the 50-day SMA on August 21. PDS Biotechnology Corporation (PDSB) stock is up 5.73% over the week and -22.57% over the past month. Its price is 11.32% year-to-date and -50.17% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.19 above consensus estimates by $0.04. The company’s next earnings report is expected on 11/05/2020, with forecasts estimating quarterly EPS at -$0.2 and -$1.09 for whole year. PDSB’s earnings per share are forecast to grow by 24.30% this year and 110.10% over next year.

Its 12-month price target is $8.25. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $6.50, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $10.00.

Outstanding shares total 15.36M with insiders holding 35.92% of the shares and institutional holders owning 5.03% of the company’s common stock. The company has a return on equity of -105.00%. The forward price to earnings ratio is 26.11. The beta has a value of 3.17. Price to book ratio is 2.66.

According to a U.S. Securities and Exchange Commission filing, Federated Hermes Kaufmann Fund has reduced its position in PDS Biotechnology Corporation (PDSB) to 375,000 shares, mirroring a recent drop by 0.00%. Federated Hermes Kaufmann Fund dumped 0.0 shares of PDS Biotechnology Corporation common stock bringing its total worth to about $1.37 million at the end of recent close, SEC documents show. Federated Hermes Kaufmann Fund isn’t the only investment manager who changed stakes and is followed by Fidelity Extended Market Index Fu, which sold off 0.0 shares to end up with 70,256 shares worth $0.26 million. Vanguard Extended Market Index Fu raise their holdings by 115.72% in the company over the course of the most recent quarter. It now holds a 0.21% position in PDS Biotechnology Corporation thanks to 31726.0 shares amounting to $0.12 million.